Lutetium-177 (Lu-177) is a beta-emitting radioactive isotope that has emerged as a revolutionary treatment for late-stage prostate cancer and neuroendocrine tumours. Lu-177 therapies target and destroy cancer cells with remarkable precision, leaving healthy tissue unharmed. However, producing Lu-177 requires bombarding ytterbium-176 (Yb-176) targets with neutrons in high-flux nuclear research reactors, of which there are only a handful operating worldwide (primarily in Germany, Belgium, Australia, and the US).
The production process is exceptionally time-critical; because Lu-177 has a half-life of just 6.7 days, it cannot be stockpiled. Any delay in the supply chain—from a reactor shutdown to a flight cancellation—renders the isotope useless. Several research reactors are decades old and require scheduled maintenance shutdowns, which routinely disrupt global supply. Furthermore, enriching the precursor isotope, Yb-176, is highly technical and historically concentrated in Russia, though new enrichment facilities are slowly being developed in North America.
To secure future supply, pharmaceutical giants are signing long-term supply agreements and funding the construction of dedicated medical isotope reactors. Governments are also stepping in to streamline regulatory approvals for nuclear-medicine transport and processing facilities. However, constructing a new research reactor takes over a decade and costs hundreds of millions of dollars, alongside meeting rigorous safety and non-proliferation standards.
With reference to Extract A and your own knowledge, assess whether the supply of Lutetium-177 (Lu-177) is likely to be price elastic or price inelastic.
